(12/14/15) | In 2015, OCRF grantees made several significant advances in the fight against ovarian cancer, including: These discoveries are the direct result of generous donations from people like you. Progress is made every day, and the future is full of promise – with even more important successes to come. Thank you for supporting cutting-edge … Continued
Last week the United States Preventive Services Task Force (USPSTF) released its fifth report to Congress highlighting women’s health as a high priority gap in clinical preventative services. Recognizing the reproductive and biologic differences in women, as well as such external factors as home and work environments and economic and educational resources, the USPSTF has … Continued
(December 4, 2015) According to the results of a phase III trial of over 1,000 women, women with advanced ovarian cancer gained significant delays in the progression of their disease when they were treated with the drug nintedanib plus carboplatin/paclitaxel, compared with women treated with carboplatin/paclitaxel alone. The results of the study were published in … Continued
2015 marks the 10th anniversary of the Colorado Ovarian Cancer Alliance (COCA), an organization dedicated to promoting awareness and early detection of ovarian cancer through advocacy and education efforts, while also providing support to women affected by ovarian cancer. COCA got its start in 2005, when a local ovarian cancer support group decided to form … Continued
In September, a group of ladies from Collierville, TN hosted their first Teal Tea Luncheon to support the Ovarian Cancer National Alliance. The community event included tea, lunch and speaker Susan Leighton who spoke about the signs and symptoms of ovarian cancer. At the luncheon, they hosted a silent auction with donations from the community. … Continued
(December 2, 2015) Research funded in part by an OCRF grant to Rachel Grisham, MD has identified new, potentially targetable mutations in patients with low grade serous ovarian cancer. Dr. Grisham is a medical oncologist at Memorial Sloan Kettering Cancer Center in New York and is a 2014 recipient of the Liz Tilberis Early Career … Continued
(December 1, 2015) Research funded in part by Ovarian Cancer Research Fund, and published in PNAS, offers new insights into how ovarian cancer grows—and the potential to stop it. Can any cancer cell form another tumor, or is it only select cancer stem cells that give rise to new cancer cells? The answer, a new … Continued
(November 20, 2015) A study published in BMC Cancer demonstrates that ovarian cancer patients who had a history of oral contraceptive use had better outcomes than those who had not previously used them. Dr. Aminah Jatoi and co-author Dr. Ellen Goode, both of the Mayo Clinic, examined 1,398 cases during a thirteen year period and … Continued
(Nov. 19, 2016) In research published this month in Gynecologic Oncology, a group of Canadian researchers have found that long-term survival is not associated with BRCA mutation status in ovarian cancer patients. Past research has shown that after a diagnosis of ovarian cancer, positive BRCA mutation status confers a mortality benefit that diminishes with time. In … Continued
November 18, 2015 Contact: Lisa Mauti lmauti@ovariancancer.org Public health evidence points to need for FDA regulation of laboratory developed tests “The consequences of inaccurate test results, such as false positives, can result in the unnecessary removal of a woman’s ovaries. It is critical that patients know their test results can be trusted.” Washington, DC — … Continued
Washington, DC — On November 17th, the Food and Drug Administration (FDA) released a report: The Public Health Evidence for FDA Oversight of Laboratory Developed Tests: 20 Case Studies, that outlines the harm that not regulating laboratory developed tests (LDTs) can cause to patients and to the economy. Included in the report were two case studies about … Continued
OCRF has awarded $5.2 million in new grants, bringing our total investment in ovarian cancer research to nearly $70 million.
Get email updates about research news, action alerts, and ways to join the fight.
